Checkpoint Therapeutics Inc. (NASDAQ: CKPT) stock declined by 1.02% at last close whereas the CKPT stock price gains by 7.88% in the pre market session. Checkpoint Therapeutics is basically a company related to immunotherapy and targeted oncology. They focus on the purchase, production, and marketing of new medicines for solid tumour cancer patients.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
CKPT stock’ Recent Update
The company reported that the CONTERNO trial which is a worldwide, randomised Phase 3 trial of cosibelimab in conjunction with pemetrexed and platinum chemotherapy for the first-line care of patients with non-squamous non-small cell lung cancer, has started. Rate of survival (OS) is the main goal for the CONTERNO Phase 3 trial, which is developed to assist full regulatory approvals globally.
The CONTERNO trial compares cosibelimab (1200 mg every three weeks) with pemetrexed and the platinum chemotherapy selected by investigator (carboplatin or cisplatin) in individuals with previously unmanaged stage IV non-squamous NSCLC and no EGFR mutations or ALK translocations to pemetrexed and platinum chemotherapy alone in patients with previously untreated stage IV non-squamous NSCLC and no EGFR mutations OS is the most important endpoint. Progression-free survival, objective response rate, and safety are all important secondary goals. A total of 560 people will be randomly assigned to receive cosibelimab in combination with chemotherapy or chemotherapy alone in a 2:1 ratio.
While giving his remarks, James F. Oliviero, President and CEO of Checkpoint, said that,they’re looking forward to testing this combination in NSCLC, with the aim of increasing the lifespan of lung cancer patients and removing barriers to possible life-saving immunotherapy medication. Since their inception, the objective has been to approach the biggest markets in this category with an emphasis on extremely competitive pricing, and there is no more important indication to follow through on this strategy than NSCLC, which is expected to grow by 1.7 million additional cases globally by 2020.